Cargando…

Clinical MR imaging in Parkinson’s disease: How useful is the swallow tail sign?

BACKGROUND: With conventional MRI, no Parkinson's disease (PD)‐specific abnormalities can be detected. However, there is a critical need for accompanying neuroimaging markers to guide the diagnosis. With high‐resolution susceptibility‐weighted MRI (SWI) sequences, the imaging of nigrosome‐1 (N1...

Descripción completa

Detalles Bibliográficos
Autores principales: Prasuhn, Jannik, Neumann, Alexander, Strautz, Robert, Dreischmeier, Shalida, Lemmer, Felicitas, Hanssen, Henrike, Heldmann, Marcus, Schramm, Peter, Brüggemann, Norbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323030/
https://www.ncbi.nlm.nih.gov/pubmed/34032020
http://dx.doi.org/10.1002/brb3.2202
_version_ 1783731166397857792
author Prasuhn, Jannik
Neumann, Alexander
Strautz, Robert
Dreischmeier, Shalida
Lemmer, Felicitas
Hanssen, Henrike
Heldmann, Marcus
Schramm, Peter
Brüggemann, Norbert
author_facet Prasuhn, Jannik
Neumann, Alexander
Strautz, Robert
Dreischmeier, Shalida
Lemmer, Felicitas
Hanssen, Henrike
Heldmann, Marcus
Schramm, Peter
Brüggemann, Norbert
author_sort Prasuhn, Jannik
collection PubMed
description BACKGROUND: With conventional MRI, no Parkinson's disease (PD)‐specific abnormalities can be detected. However, there is a critical need for accompanying neuroimaging markers to guide the diagnosis. With high‐resolution susceptibility‐weighted MRI (SWI) sequences, the imaging of nigrosome‐1 (N1) is possible. The so‐called swallow tail sign (STS) has been proposed as a suitable neuroimaging marker for the diagnosis of PD. OBJECTIVES: To investigate whether the absence of the STS can be applied for distinguishing PD patients from healthy controls (HCs). METHODS: SWI images of 44 PD patients and 50 age‐ and gender‐matched HCs were investigated using a 3T MRI scanner. Two trained neuroradiologists blind‐rated the images and evaluated whether the STS was absent (1) on one side or (2) both sides of the participant's midbrain. RESULTS: Our results confirmed good interrater reliability comparable to previously published studies. However, we did not identify any group differences between PD patients and HCs. Measures of diagnostic values revealed overall poor diagnostic performance. CONCLUSIONS: Even though previously stated, our study does not confirm the potential use of the STS as a supportive neuroimaging marker for PD in a clinical setting. In conclusion, there is a critical need for improvements in N1‐targeted MRI sequences and the development of advanced segmentation algorithms.
format Online
Article
Text
id pubmed-8323030
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-83230302021-08-04 Clinical MR imaging in Parkinson’s disease: How useful is the swallow tail sign? Prasuhn, Jannik Neumann, Alexander Strautz, Robert Dreischmeier, Shalida Lemmer, Felicitas Hanssen, Henrike Heldmann, Marcus Schramm, Peter Brüggemann, Norbert Brain Behav Original Research BACKGROUND: With conventional MRI, no Parkinson's disease (PD)‐specific abnormalities can be detected. However, there is a critical need for accompanying neuroimaging markers to guide the diagnosis. With high‐resolution susceptibility‐weighted MRI (SWI) sequences, the imaging of nigrosome‐1 (N1) is possible. The so‐called swallow tail sign (STS) has been proposed as a suitable neuroimaging marker for the diagnosis of PD. OBJECTIVES: To investigate whether the absence of the STS can be applied for distinguishing PD patients from healthy controls (HCs). METHODS: SWI images of 44 PD patients and 50 age‐ and gender‐matched HCs were investigated using a 3T MRI scanner. Two trained neuroradiologists blind‐rated the images and evaluated whether the STS was absent (1) on one side or (2) both sides of the participant's midbrain. RESULTS: Our results confirmed good interrater reliability comparable to previously published studies. However, we did not identify any group differences between PD patients and HCs. Measures of diagnostic values revealed overall poor diagnostic performance. CONCLUSIONS: Even though previously stated, our study does not confirm the potential use of the STS as a supportive neuroimaging marker for PD in a clinical setting. In conclusion, there is a critical need for improvements in N1‐targeted MRI sequences and the development of advanced segmentation algorithms. John Wiley and Sons Inc. 2021-05-24 /pmc/articles/PMC8323030/ /pubmed/34032020 http://dx.doi.org/10.1002/brb3.2202 Text en © 2021 The Authors. Brain and Behavior published by Wiley Periodicals LLC https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Prasuhn, Jannik
Neumann, Alexander
Strautz, Robert
Dreischmeier, Shalida
Lemmer, Felicitas
Hanssen, Henrike
Heldmann, Marcus
Schramm, Peter
Brüggemann, Norbert
Clinical MR imaging in Parkinson’s disease: How useful is the swallow tail sign?
title Clinical MR imaging in Parkinson’s disease: How useful is the swallow tail sign?
title_full Clinical MR imaging in Parkinson’s disease: How useful is the swallow tail sign?
title_fullStr Clinical MR imaging in Parkinson’s disease: How useful is the swallow tail sign?
title_full_unstemmed Clinical MR imaging in Parkinson’s disease: How useful is the swallow tail sign?
title_short Clinical MR imaging in Parkinson’s disease: How useful is the swallow tail sign?
title_sort clinical mr imaging in parkinson’s disease: how useful is the swallow tail sign?
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323030/
https://www.ncbi.nlm.nih.gov/pubmed/34032020
http://dx.doi.org/10.1002/brb3.2202
work_keys_str_mv AT prasuhnjannik clinicalmrimaginginparkinsonsdiseasehowusefulistheswallowtailsign
AT neumannalexander clinicalmrimaginginparkinsonsdiseasehowusefulistheswallowtailsign
AT strautzrobert clinicalmrimaginginparkinsonsdiseasehowusefulistheswallowtailsign
AT dreischmeiershalida clinicalmrimaginginparkinsonsdiseasehowusefulistheswallowtailsign
AT lemmerfelicitas clinicalmrimaginginparkinsonsdiseasehowusefulistheswallowtailsign
AT hanssenhenrike clinicalmrimaginginparkinsonsdiseasehowusefulistheswallowtailsign
AT heldmannmarcus clinicalmrimaginginparkinsonsdiseasehowusefulistheswallowtailsign
AT schrammpeter clinicalmrimaginginparkinsonsdiseasehowusefulistheswallowtailsign
AT bruggemannnorbert clinicalmrimaginginparkinsonsdiseasehowusefulistheswallowtailsign